A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors

Molecular Therapy

Volumn 14, Issue 2, 2006, Pages 276-284

  Cockrell, Adam S ^a   Ma, Hong ^a   Fu, Kailing ^a   McCown, Thomas J ^a   Kafri, Tal ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

conditional SIN vector; gene therapy; inducible gene expression; lentivirus; packaging cell; tetracycline; trans lentiviral; vector

Indexed keywords

GAG PROTEIN; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; POL PROTEIN; RETROVIRUS VECTOR;

ARTICLE; CELL CLONE; CELL LINE; CONTROLLED STUDY; FIBROBLAST; GENE CASSETTE; GENE EXPRESSION; GENETIC TRANSDUCTION; GENOME; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERNAL RIBOSOME ENTRY SITE; PHENOTYPE; TARGET CELL; TRANSGENE; VIRUS INACTIVATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745664380     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.12.015     Document Type: Article

References (27)

1. Ikeda Y., Takeuchi Y., Martin F., Cosset F.L., Mitrophanous K., and Collins M. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21 (2003) 569-572
2. Ni Y., et al. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J. Gene Med. 7 (2005) 818-834
3. Wu X., et al. Development of a novel trans-lentiviral vector that affords predictable safety. Mol. Ther. 2 (2000) 47-55
4. -) cells. J. Virol. 74 (2000) 10994-11000
5. Paxton W., Connor R.I., and Landau N.R. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J. Virol. 67 (1993) 7229-7237
6. Zhu H., Jian H., and Zhao L.J. Identification of the 15FRFG domain in HIV-1 Gag p6 essential for Vpr packaging into the virion. Retrovirology 1 (2004) 26
7. Wu X., et al. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J. Virol. 69 (1995) 3389-3398
8. Wu X., Liu H., Xiao H., Conway J.A., Hunter E., and Kappes J.C. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J. 16 (1997) 5113-5122
9. Stewart S.A., Poon B., Jowett J.B., and Chen I.S. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J. Virol. 71 (1997) 5579-5592
10. Konvalinka J., et al. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity. J. Virol. 69 (1995) 7180-7186
11. Li Y., Drone C., Sat E., and Ghosh H.P. Mutational analysis of the vesicular stomatitis virus glycoprotein G for membrane fusion domains. J. Virol. 67 (1993) 4070-4077
12. Blau H.M., and Rossi F.M.V. Tet B or not tet B: advances in tetracycline-inducible gene expression. Proc. Natl. Acad. Sci. USA 96 (1999) 797-799
13. Kafri T., van Praag H., Ouyang L., Gage F.H., and Verma I.M. A packaging cell line for lentivirus vectors. J. Virol. 73 (1999) 576-584
14. Klages N., Zufferey R., and Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther. 2 (2000) 170-176
15. Bukovsky A.A., Song J.P., and Naldini L. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol. 73 (1999) 7087-7092
16. Lucke S., Grunwald T., and Uberla K. Reduced mobilization of Rev-responsive element-deficient lentiviral vectors. J. Virol. 79 (2005) 9359-9362
17. Xu K., Ma H., McCown T.J., Verma I.M., and Kafri T. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther. 3 (2001) 97-104
18. Jacks T., Madhani H.D., Masiarz F.R., and Varmus H.E. Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell 55 (1988) 447-458
19. Srinivasakumar N., Chazal N., Helga-Maria C., Prasad S., Hammarskjold M.L., and Rekosh D. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J. Virol. 71 (1997) 5841-5848
20. Kaul M., Yu H., Ron Y., and Dougherty J.P. Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences. Virology 249 (1998) 167-174
21. Farson D., et al. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum. Gene Ther. 12 (2001) 981-997
22. Pacchia A.L., Adelson M.E., Kaul M., Ron Y., and Dougherty J.P. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology 282 (2001) 77-86
23. Sparacio S., Pfeiffer T., Schaal H., and Bosch V. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol. Ther. 3 (2001) 602-612
24. Chen S.W., Chiu H.C., Liao W.H., Wang F.D., Chen S.S., and Wang C.T. The virus-associated human immunodeficiency virus type 1 Gag-Pol carrying an active protease domain in the matrix region is severely defective both in autoprocessing and in trans processing of gag particles. Virology 318 (2004) 534-541
25. Loew R., et al. Simplified generation of high-titer retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of a lox-P-flanked marker gene. Mol. Ther. 9 (2004) 738-746
26. Morris J.C., Conerly M., Thomasson B., Storek J., Riddell S.R., and Kiem H.P. Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood 103 (2004) 492-499
27. Naldini L., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267